The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.

Gilead Sciences (NASDAQ:GILD) has discontinued a Phase 1 trial for GS-1219, a long-acting subcutaneously delivered treatment ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

Lenacapavir is a first-in-class, long-acting HIV-1 capsid inhibitor designed to inhibit HIV replication at multiple stages of its lifecycle. The Food and Drug Administration (FDA) has approved ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

A Prescription Drug User Fee Act target date of April 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir ...

In a recent landmark study, scientists have unveiled how HIV-1 penetrates the cell's nuclear barrier—a discovery that could reshape antiviral strategies. The research, led by Professor Peijun Zhang, ...

Some HIV-1 carriers who have received an early antiretroviral treatment during several years are able to control the virus for a long term after treatment interruption. However, the mechanisms ...

South Africa has made history by becoming the first African nation to register Lenacapavir, a revolutionary long-acting ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New ...